Holen Sie sich die Stockscreener-App
2.39
2.45%
-0.06
Schlusskurs vom Vortag:
$2.45
Offen:
$2.45
24-Stunden-Volumen:
126.85K
Relative Volume:
0.67
Marktkapitalisierung:
$237.63M
Einnahmen:
$4.60M
Nettoeinkommen (Verlust:
$-82.31M
KGV:
-2.9139
EPS:
-0.8202
Netto-Cashflow:
$-87.79M
1W Leistung:
-4.40%
1M Leistung:
-9.81%
6M Leistung:
-22.15%
1J Leistung:
-19.26%
1-Tages-Spanne:
$2.38
$2.47
1-Wochen-Bereich:
$2.35
$2.50
52-Wochen-Spanne:
$2.095
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.39 | 237.63M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-31 | Eingeleitet | BTIG Research | Buy |
| 2019-02-01 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-04 | Eingeleitet | UBS | Buy |
| 2018-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-10-18 | Eingeleitet | Jefferies | Buy |
| 2016-10-18 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Ac Immune Sa Aktie (ACIU) Neueste Nachrichten
AC Immune SA (HAM:IMR) Stock Price, Trades & News - GuruFocus
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Shareholders elect Tom Graney to AC Immune (ACIU)'s board through the 2027 annual meeting. - Stock Titan
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - Zacks Investment Research
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
Best Momentum Stock to Buy for September 30th - Zacks Investment Research
Average basic shares outstanding of AC Immune SA – HAN:IMR - TradingView
Long term debt to total equity ratio of AC Immune SA – HAN:IMR - tradingview.com
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Zacks Investment Research
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals - Yahoo Finance
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions (NASDAQ:ACIU) - Seeking Alpha
H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com
AC Immune says ACI-7104 shows durable immunogenicity - The Pharma Letter
AC Immune (NasdaqGM:ACIU) Stock Forecast & Analyst Predictions - Simply Wall Street
AC Immune SA (ACIU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response - Benzinga
AC Immune posts trial data for Parkinson’s drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune reports positive phase 2 trial results for ACI-7104 - Investing.com
AC Immune reports positive phase 2 trial results for Parkinson’s drug - Investing.com
AC Immune reports positive phase 2 trial results for Parkinson’s drug - Investing.com UK
Experimental Parkinson’s treatment from AC Immune (NASDAQ: ACIU) sparks immune response in early trial - Stock Titan
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 - Yahoo Finance UK
After 100 weeks, AC Immune's Parkinson's trial met its main safety and immune-response goals. - Stock Titan
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 - GlobeNewswire
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Zacks Investment Research
AC Immune SA Share PriceACIU, RNS News, Articles, Quotes, & Charts (NASDAQ:ACIU) - Proactive financial news
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - Zacks Investment Research
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - Zacks Investment Research
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus - TipRanks
AC Immune SA (NASDAQ: ACIU) Schedules October 2 Vote for Tom Graney's Board Nomination - Kalkine Media
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board - TipRanks
Parkinson's drug Fast Tracked as AC Immune (NASDAQ: ACIU) plans board changes - Stock Titan
AC Immune Ltd (NASDAQ: ACIU) Share Price, ACIU Stock News, ACIU Share Price & Updates - kalkine.ca
AC Immune reports positive phase 1 data for ACI‑19764 - PharmaTimes
AC Immune stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor - pharmaphorum
AC (ACIU) Financial Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Market Price Moves 2.33% Higher on the DayConsensus Forecast Report - vinanet.vn
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline - Benzinga
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study - AllSci
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 - Yahoo Finance
AC Immune stock gains on early Phase 1 trial results By Investing.com - Investing.com Australia
AC Immune stock gains on early Phase 1 trial results - Investing.com
AC Immune stock gains on early Phase 1 trial results - Investing.com India
Finanzdaten der Ac Immune Sa-Aktie (ACIU)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ac Immune Sa-Aktie (ACIU) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ANDREA M.A PFEIFER | Director |
May 15 '26 |
Proposed Sale |
2.80 |
20,000 |
56,000 |
0 |
| ANDREA M.A PFEIFER | Officer |
Apr 15 '26 |
Proposed Sale |
3.19 |
10,000 |
31,900 |
0 |
| ANDREA M.A PFEIFER | Officer |
Jan 15 '26 |
Proposed Sale |
3.67 |
30,000 |
110,100 |
0 |
| ANDREA M.A PFEIFER | Officer |
Oct 03 '25 |
Proposed Sale |
3.13 |
45,000 |
140,850 |
0 |
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):